Reportstack

OpportunityAnalyzer: Uveitis - Opportunity Analysis and Forecasts to 2017

 
Repost This

Naperville, IL -- (SBWIRE) -- 12/30/2013 -- Reportstack, provider of premium market research reports announces the addition of OpportunityAnalyzer: Uveitis - Opportunity Analysis and Forecasts to 2017 market report to its offering
Uveitis is an expanding market currently dominated by corticosteroid treatment options as well as off-label immunosuppressive and biologic drugs. Since the conventional corticosteroid treatment is only effective in 50-60% of patients a significant number of patients can be targeted with the new treatment options. While anterior uveitis patients represent the majority of patients, all but one of the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. The uveitis market is expected to grow between 2012 and 2017, due to the introduction of biologic drugs as well as a diversification of administrative routes. Market growth is created by the increase in treatment costs and will continue beyond the forecasted time period. The new treatments will target some key unmet needs but opportunities will remain for drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile.

Scope

- Overview of uveitis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized uveitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for five years to 2017.

- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the uveitis therapeutics market.

- Pipeline analysis: focus on the five late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.

- Analysis of the current and future market competition in the global uveitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Questions Answered

- The uveitis market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the uveitis market?

- The late-stage uveitis pipeline is filled with diverse molecules and routes of administration. Which drug will have a significant impact on the uveitis market. Which of these drugs will have the highest CAGR, and why?

- The current uveitis market is dominated by corticosteroids as well as off-label immunosuppressive and biologic drugs. How will the introduction of biologic drugs change the treatment landscape once reimbursement is not a problem anymore? How will the drug treatment rates change over the next five years? What are the key drivers and barriers to this change?

Key Findings

- The main driver of the expansion of the uveitis market will be the introduction of biologic drugs, which will increase the market size significantly. The introduction of new ocular administration routes will strengthen the market growth further.

- An additional driver for the uveitis market is the assignment of orphan drug status to several uveitis drugs.

- The biggest barrier for the introduction of the more costly treatment options like biologics will be reimbursement especially in the European markets. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively.

- Pipeline drugs developed by small to mid-size pharma companies represent a good opportunity for companies to enter the uveitis market and to strengthen their ophthalmology department.

Key Benefits

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop business strategies by understanding the trends shaping and driving the global uveitis therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global uveitis therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global uveitis therapeutics market from 2012-2017.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

List of Companies

AbbVie Inc.

Alcon, Inc.

Alimera Sciences, Inc.

Bausch & Lomb Inc.

Enzo Biochem, Inc.

Eyegate Pharmaceuticals, Inc.

Hoffman-La Roche Inc.

Icon Plc.

MacuSight, Inc.

Novartis AG

Ophthalix Inc.

pSivida Corp.

Regeron Inc.

Sanofi

Santen Pharmaceutical Co., Ltd.

Senju Phar.aceutical Co., Ltd.

Valeant Pharmaceuticals International, Inc.

Xoma Corp

Report at a Glance

Number of Companies Mentioned – 18

Number of Marketed and Pipeline Drugs Mentioned –19

Major Pipeline Drugs Mentioned – 5 Phase III drugs.

Markets Covered – US, France, Germany, Italy, Spain, UK.

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/148225/opportunityanalyzer-uveitis-opportunity-analysis-and-forecasts-to-2017.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###